Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Annals of Surgical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1245/s10434-016-5203-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30.

  2015cited by this paper
• Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone

  2014cited by this paper
• Quality of Life in Peritoneal Carcinomatosis: A Prospective Study in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  2014cited by this paper
• Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  2014cited by this paper
• Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.

  2014cited by this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Asian Patients: 100 Consecutive Patients in a Single Institution

  2013cited by this paper
• Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ-C30?

  2012influential reference
• Quality of Life in Patients after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is It Worth the Risk?

  2012cited by this paper
• The American Society of Peritoneal Surface Malignancies (ASPSM)

  2011cited by this paper
• Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin

  2011cited by this paper
• Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

  2009cited by this paper
• Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality

  2009cited by this paper
• Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

  2008cited by this paper
• Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

  2007cited by this paper
• Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy

  2006cited by this paper
• Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

  2006cited by this paper
• Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  2005cited by this paper
• Long-Term Survivorship and Quality of Life After Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

  2003cited by this paper
• Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.

  2001cited by this paper

• Are current scales adequate for assessing quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

  2025cites this paper
• Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: A Qualitative Exploration of the Lived Experiences of Patients and Carers

  2025cites this paper
• Response to comment on “Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: A retrospective single center experience”

  2025cites this paper
• Overview: Challenges of Treating Peritoneal Surface Malignancies.

  2024cites this paper
• Analyzing quality of life after low anterior resection for rectal cancer

  2024cites this paper
• Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial

  2023influential citation
• Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy

  2022cites this paper
• Can baseline quality of life scores predict for morbidity and survival after CRS and HIPEC: a prospective study of 151 patients

  2022cites this paper
• Depression, Anxiety, Stress and Distress Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Prospective Cohort Study

  2022cites this paper
• Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

  2022cites this paper
• Functional Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Cohort Study

  2022cites this paper
• Organ-Specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

  2022cites this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review

  2021influential citation
• Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Early Results from a Prospective Cohort Study of 115 Patients

  2020cites this paper
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) for Colorectal Cancer: Potential for Individualized Care, Review of Current Treatment Trends, Recent Advancements, and a Look into the Future

  2019cites this paper
• Does having a gastrectomy delay time to feeding and prolong hospital stay in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

  2018cites this paper
• Malignant hydrocele: a rare manifestation of peritoneal carcinomatosis of colorectal origin as a transcoelomic spread into the scrotum – case report and literature overview

  2018cites this paper
• Pleura and Peritoneum

  2018cites this paper
• Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

  2018cites this paper
• Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer

  2017cites this paper
• Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis

  2017cites this paper
• Qualité de vie et résultat à court terme après chimiothérapie intra- Peritoneale vaporisée (PIPAC) chez les patients atteints de carcinose péritonéale

  2017cites this paper
• Data on the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: does it concern patients with gastric cancer?

  2017cites this paper
• Pleura and Peritoneum

  2017cites this paper
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin

  2017cites this paper
• Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study

  2017cites this paper
• Therapeutic options for peritoneal metastasis arising from colorectal cancer.

  2016cites this paper